Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-month, Prospective, Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Treatment Naïve Patients (According to Standard Clinical Practice) With Diabetic Macular Edema

NCT03953807 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT03953807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03953807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-month, Prospective, Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Treatment Naïve Patients (According to Standard Clinical Practice) With Diabetic Macular Edema
Lead sponsor
Allergan
Phase
Phase 4
Overall status
Completed
Start date
September 5, 2019
Completion date
July 4, 2022
Enrollment
82 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema